[1]蒋长青,王丹丹,王翔宇,等. 原发性外阴及阴道恶性黑色素瘤临床病理分析[J].青岛大学学报(医学版),2018,54(03 ):338-341.[doi:10.11712/jms201803020]
 JIANG Changqing,WANG Dandan,WANG Xiangyu,et al. PRIMARY MALIGNANT MELANOMA OF THE VULVA AND VAGINA: A REPORT OF 5 CASES[J].JOURNAL OF QINGDAO UNIVERSITY (MEDICAL SCIENCES),2018,54(03 ):338-341.[doi:10.11712/jms201803020]
点击复制

 原发性外阴及阴道恶性黑色素瘤临床病理分析()
分享到:

《青岛大学学报(医学版)》[ISSN:2096-5532/CN:37-1217/R]

卷:
第54卷
期数:
2018年03 期
页码:
338-341
栏目:
出版日期:
2018-05-29

文章信息/Info

Title:
 PRIMARY MALIGNANT MELANOMA OF THE VULVA AND VAGINA: A REPORT OF 5 CASES
作者:
 蒋长青王丹丹王翔宇崔竹梅
 青岛大学附属医院妇科,山东 青岛 266061
Author(s):
 JIANG Changqing WANG Dandan WANG Xiangyu CUI Zhumei
 Department of Gynaecology, The Affiliated Hospital of Qingdao University, Qingdao 266061, China
关键词:
 黑色素瘤外阴肿瘤阴道肿瘤治疗预后
Keywords:
 melanoma vulvar neoplasms vaginal neoplasms therapy prognosis
分类号:
R737.3
DOI:
10.11712/jms201803020
文献标志码:
A
摘要:
 目的 探讨原发性外阴、阴道恶性黑色素瘤的临床病理特点、诊断、治疗和预后。
方法 回顾性分析2010—2016年我院收治的5例原发性外阴、阴道恶性黑色素瘤病人的临床资料。
结果 术前活检3例诊断为阴道恶性黑色素瘤,1例为外阴恶性黑色素瘤,1例为子宫腺肉瘤。术后病理及免疫组化检查4例确诊为阴道恶性黑色素瘤,1例为外阴恶性黑色素瘤;HMB45阳性5例,Melan-A阳性4例,S-100阳性4例。所有病人均接受手术治疗,1例接受免疫治疗及辅助放疗,1例接受辅助化疗;5例病人均死于外阴、阴道恶性黑色素瘤及其并发症,平均生存期为438 d,中位生存期为283 d,1年无瘤生存率为0,1年总生存率为40%,2年总生存率为20%。
结论 外阴、阴道恶性黑色素瘤恶性程度高、病死率高、预后差,免疫组化HMB45、S-100检查可提高确诊率,合理的系统治疗是预后的关键。
Abstract:
 Objective To investigate the clinical characteristics, diagnosis, treatment, and prognosis of patients with primary malignant melanoma of the vulva or vagina.
Methods A retrospective analysis was conducted on the clinical data of 5 patients with primary malignant melanoma of the vulva or vagina, who were admitted to the Affiliated Hospital of Qingdao University from 2010 to 2016.
Results Preoperative biopsies revealed that 3 patients had primary malignant melanoma of the vagina,1 patient had primary malignant melanoma of the vulva, and 1 patient had uterine adenosarcoma. Postoperative pathological and immunohistochemical examinations indicated that 4 patients had a definitive diagnosis of primary malignant melanoma of the vagina, and 1 patient had a definitive diagnosis of primary malignant melanoma of the vulva. The numbers of patients with HMB45-positive, Melan-A positive, and S-100 positive results were 5,4, and 4, respectively. All the 5 patients had undergone surgical therapy. In addition,1 patient received immunotherapy and adjuvant radiotherapy, while 1 patient received adjuvant chemotherapy. All the 5 patients died from primary malignant melanoma of the vulva or vagina, or its complications. The mean survival time was 438 d and the median survival time was 283 days. The one-year tumor-free survival rate was 0, the one-year overall survival rate was 40%, and the two-year overall survival rate was 20%.
Conclusion Malignant melanoma of the vulva or vagina is a tumor of high malignancy with high mortality and poor prognosis. Immunohistochemical examination of HMB45 and S-100 can increase the possibility to achieve a definitive diagnosis of the disease. Proper systematic treatment is the key factor for a favorable prognosis.
更新日期/Last Update: 2018-06-05